Recently Featured

Bristol Myers Considers Houston for Potential $1B Manufacturing Plant

June 10, 2026
Bristol Myers Squibb is actively exploring locations for a significant manufacturing facility in the United States, with Houston emerging as a leading candidate for a potential $1 billion investment. This development signals the company’s commitment to expanding its production capabilities amidst growing demand for its pharmaceutical products. The selection of Houston aligns with the city’s…

FDA Approves AstraZeneca’s Baxdrostat for Patients with Hypertension

June 10, 2026
The FDA has granted approval for AstraZeneca’s baxdrostat, a novel treatment targeting specific patients with hypertension. This regulatory milestone is significant as it aligns with AstraZeneca’s ambitious strategy to achieve $80 billion in revenue by 2030, positioning baxdrostat as a key component of their product portfolio. The approval comes at a time when hypertension management…

Tracy Beth Høeg Ousted from FDA in Wider Senior Leadership Shakeup

June 10, 2026
Tracy Beth Høeg, a prominent figure within the FDA, has been ousted amid a broader leadership shakeup within the U.S. Department of Health and Human Services (HHS). This significant change comes as the Republican Party seeks to consolidate voter support ahead of the upcoming midterm elections, indicating a strategic maneuver to align health policy with…

Japan’s MHLW Approves Boehringer’s Jascayd for IPF and PPF

June 10, 2026
Boehringer Ingelheim has secured approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for Jascayd (nerandomilast), a significant advancement in the treatment landscape for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). This approval marks a pivotal moment for patients suffering from these debilitating conditions, as Jascayd offers a new therapeutic option aimed…

Ongoing Cases